Citations

Clear

140 citation(s) found for "Mahesh, P A".

Snare‐Assisted Retrieval of a Mechanically Locked‐Open TEER Device: A Novel Bailout Technique
Kaliyamoorthy, Dhamodaran , Murugesan, Kannan , Mahesh Kumar, Aishwarya

Mayo Clinic

Catheterization and Cardiovascular Interventions | October 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ccd.70957 | PMID 42949126 Get It

ABSTRACT Transcatheter edge‐to‐edge repair (TEER) is an established intervention for patients having severe mitral regurgitation (MR) with prohibitive surgical risk. Complications during deployment related to device malfunction are uncommon but necessitate prompt decision‐making and management. A 54‐year‐old gentleman with dilated cardiomyopathy, severe left ventricular dysfunction, and severe MR underwent TEER using the MyClip system (Meril Life Sciences Pvt. Ltd., Vapi, Gujarat, India). Initial deployment across the A2−P2 scallops of mitral leaflets achieved partial MR reduction. Significant residual MR required a second clip for optimal leaflet coaptation. While deploying the second clip, it failed to close because of a mechanical locking failure. So, we everted the clip, pulled back to LA, and it stayed in open position and failed to close. We report a novel bailout snare technique that enabled safe retrieval without the need for a second transseptal puncture. The ability to close the clip arms prior to withdrawal minimized the risk of tearing the atrial septum and facilitated the successful completion of the TEER procedure. Another clip was deployed successfully, resulting in significant MR reduction. This case demonstrates a rare complication during deployment, a malfunction of the device, and a novel strategy for safely bailing out a challenging intra‐procedural complication.
Transcatheter Aortic Valve Replacement is Associated With a Lower Risk of Aortic Dissection Than Surgical Aortic Valve Replacement: A Propensity Score-Matched Analysis
Doma, Mohamed , Kritya, Mangesh , Ramadan, Adham, Félix, Iuri Ferreira , Shlkamy, Seif, Lingamsetty, Shanmukh Sai Pavan , Ismayl, Mahmoud , Mahesh, Ashwin, Ferreira Felix, Iuri , Lingamsetty, Shanmukh S P , Ismayl, Mahmoud , Goldsweig, Andrew M , Doma, Mohamed , Ramadan, Adham, Kamel, Ibrahim, Mahmoud, Ahmed , Goldsweig, Andrew M.

Mayo Clinic

Reviews in Cardiovascular Medicine | July 30, 2026 | Volume: 27 | Issue: 7 | Pages: No page available

10.31083/rcm50574 | PMID 42534156 Get It

Background:Aortic valve replacement is the primary treatment for aortic valve disease and can be performed using either transcatheter (TAVR) or surgical (SAVR) approaches. The risk of aortic dissection (AD) with TAVR compared with SAVR remains unclear. We aimed to compare AD risk between TAVR and SAVR using a large, real-world cohort. Methods:We conducted a retrospective cohort analysis using the TriNetX research network. Patients with a diagnosis of aortic stenosis, aortic insufficiency, mixed aortic valve disease (AVD), or unspecified AVDwho underwent either TAVR or SAVR were included. A 1:1 propensity score-matching (PSM) based on baseline characteristics was performed to adjust for potential confounding. Logistic regression and Cox proportional hazards models were used to estimate odds ratios (ORs) and hazard ratios (HRs), with 95% confidence intervals (CIs).Results:Among 95,043 patients undergoing isolated aortic valve replacement, 20,237 matched pairs were analyzed after 1:1 PSM. Baseline characteristics were well balanced, with a mean age of 73.3 ± 9.3 years in the TAVR group and 73.2 ± 8.5 years in the SAVR group; 60.8% and 60.7% were male, respectively. TAVR was associated with significantly lower odds of composite AD than SAVR at all time points (1-year OR 0.60; 95% CI 0.44–0.82; 3-year OR 0.64; 95% CI 0.48–0.83; 5-year OR 0.66; 95% CI 0.51–0.85; p < 0.01 for all). Stratified analyses demonstrated lower odds of both Stanford type A and type B AD at all time points. Kaplan–Meier analysis demonstrated a separation in composite AD-free survival between the two groups (HR 0.66; 95% CI 0.51–0.86; p = 0.002).Conclusion:In this large, real-world cohort, despite a low event rate, TAVR was associated with a significantly lower likelihood of composite AD than SAVR.
Global Burden of Elevated LDL-C
Collaborators, GBD 2023 LDL Cholesterol, Razo, Christian, DeCleene, Nicole K., Johnson, Catherine O., Stark, Benjamin, LeGrand, Kate, Aalruz, Hasan, Abaraogu, Ukachukwu O., Abdelnabi, Mahmoud, Abd-Elsalam, Sherief, Abdelwahab, Siddig Ibrahim, Abdollahi, Arash, Abdrabou, Mostafa M., Abdul‐Rahman, Toufik , Getahun, Habtamu Abebe, Abiodun, Olumide, Abohashem, Shady, Abonie, Ulric Sena , Abourashed, Nagah M , Abramov, Dmitry, Abrar, Mohammed Mehdi, Farha, Rana Kamal Abu, Abubakar, Bilyaminu, Aburuz, Salahdein, Abushanab, Dina, Adams, Lisa C., Adamu, Nuhu Lawan Lawan, Adegbile, Oluwatobi E , Adegoke, Nurudeen A., Adekola, Saheed Ayodeji, Adeleke, Olumide Thomas , Adesina, Miracle Ayomikun, Afoakwah, Clifford, Afolabi, Aanuoluwapo Adeyimika, Afrashteh, Fatemeh , Afrifa-Yamoah, Ebenezer, Agyemang‐Duah, Williams , Ahmad, Suhaib, Ahmed, Asma , Ahmed, Gasha Salih, Ahmed, Luai A., Ahmed, Mehrunnisha Sharif, Ahmed, Meqdad Saleh , Ahmed, M. , Ahmed, Mushood, Ahmed, Syed Anees, Ahmed, Zohra, Aiyer, Aishwarya, Ajami, Marjan, Akalanka, Kasuni H.M. , Akhtar, Muhammad Nadeem, Akrami, Ashley E, Akyea, Ralph Kwame, Hasan, Syed Mahfuz Al , Zoubi, Mohammad Ahmmad Mahmoud Al, Alahdab, Fares , Al-Ahmad, Mohammad M. , Alajajian, Stephen , Alajlani, Muaaz , Alalwan, Tariq A., Al-Amri, Issa Sulaiman, Alanzi, Turki M., Alarifi, Abdullah, Al-Azzam, Sayer, Albashtawy, Mohammed, Al-Dewik, Nader, Algahtani, Fahad D., Algammal, Abdelazeem M, Alhalaiqa, Fadwa Naji, Ali, Mohammad Daud , Ali, Mohammed Usman, Ali, Rafat, Ali, Syed Shujait, AL-Iede, Montaha, Alipour, Morteza, Al-Jabi, Samah W., Alkhatib, Mayson H. , Allawi, Raad Hatim , Allemailem, Khaled S. , (6837737), Mohammed Z. Allouh, Almahmeed, Wael, Al-Marwani, Sabah , Almazan, Joseph Uy, Alnaeem, Mohmmad Minwer, Alotaibi, Haifa F. F., Alqahtani, Saleh A, Alqudah, Mohammad , Alqudimat, Mohammad R, Al-Qudimat, Ahmad Rajeh, Alrimawi, Intima , Alrousan, Sahel Majed, Alshahrani, Najim Z., Altaany, Zaid, Altaf, Awais, Althobiani, Malik A., Altwalbeh, Diala, Al-Worafi, Yaser Mohammed, Aly, Hany, Alzoubi, Karem H., Al-Zubairi, Adel S., Amafah, Joy, Mohammadi, Masoud Aman, Amini, Saeed, Amini-Salehi, Ehsan, Ananda, Roshan A., Ancuceanu, Robert, Anil, Abhishek, Anjana, Prapti, Anuoluwa, Boluwatife Stephen, Anvari, Saeid, Anwar, Sumadi Lukman, Anyasodor, Anayochukwu Edward , Appati, Walter, Arafa, Elshaimaa A , Aravkin, Aleksandr Y. , Areda, Demelash, Aregawi, Brhane Berhe, Torre, Jorge Arias de la, Arruda, Gustavo Aires , Asghari-Jafarabadi, Mohammad , Ashraf, Saad , Asare, Bernard Yeboah‐Asiamah , Atac, Omer, Athari, Seyyed Shamsadin, Atorkey, Prince , Aurangzeb, Khursheed, Awan, Usman Ayub , Awol, Kemal Lemnuro Lemnuro, Ayala, Camila Ospina , Ayli, Berrak Itir, Azad, A.K.M., Azzam, Ahmed Y., Babiker, Rasha, Badar, Muhammad, Badran, Alaa Aboelnour, Baghlaf, Khlood K., Balabekova, Marina, Balakrishnan, Senthilkumar , Baltatu, Ovidiu Constantin , Banach, Maciej, Bashir, Muhammad Irfan , Bashir, Shahid, Bashiri, Azadeh, Bastan, Mohammad-Mahdi, Bayat, Mahdis , Behera, Surama Manjari , Belayneh, Melesse, Bello, Abdulrahman Babatunde , Belo, Luís, Bhaskar, Sonu, Bizzozero-Peroni, Bruno, Bogale, Sitotaw Kerie, Bolourinejad, Paria , Bonny, Aimé , Carvajal, Alejandro Botero, Bouaoud, Souad, Britton, Gabrielle, Bustanji, Yasser, Butt, Zahid A., Cao, Yu, Catapano, Alberico L., Cegolon, Luca, Cembranel, Francieli , Chadwick, Joshua , Chau, Lam Duc, Chaudhary, Anis Ahmad, Chen, An-Tian, Chen, Hana, Chen, Haowei , Cheng, Haojin, Cheung, Ka Ching , Chew, Nicholas WS, Chi, Gerald, Cho, William C. S., Chong, Bryan, Chopra, Deepti, Chopra, Shivani , Cicero, Arrigo Francesco Giuseppe, Criqui, Michael H., Cruz-Martins, Natalia, Dahabiyeh, Lina, Khatri, Bishal Dahal , Dalakoti, Mayank, D’Amico, Emanuele, Damtie, Endalamaw Tesfa, Dandona, Lalit , Dandona, Rakhi, D’Anna, Lucio , Danpanichkul, Pojsakorn, Dardas, Latefa Ali , Das, Sayan Kumar, Davletov, Dimash, Dergaa, Ismail, Derseh, Hunegnaw Almaw , Desale, Aragaw Tesfaw, Devanbu, Vinoth Gnana Chellaiyan, Devegowda, Devananda, Dewan, Syed Masudur Rahman, Dhali, Arkadeep , Dhungel, Bibha, Silva, Diana Dias da, Didehvar, Kimia, Ding, Xueting, Do, Thanh Chi, Do, Thao Huynh Phuong, Dohare, Sushil, Dong, Dachuan, D’Oria, Mario, Dorostkar, Fariba, Doshi, Ojas Prakashbhai, Dresse, Menayit Tamrat , Du, Mi, Ebraheim, Lamiaa Labieb Mahmoud, Edeh, Cynthia , Eftekhari, Behrad, Sedeh, Ashkan Eighaei , Ekholuenetale, Michael , Arab, Rabie Adel El , Eldaboush, Ahmed, El-Dahiyat, Faris , Elhoumed, Mohamed, Elmeligy, Omar Abdelsadek Abdou, Elmonem, Mohamed A., Elmoselhi, Adel B., Elnaem, Mohamed Hassan , Eltahawy, Abdelgawad Salah, Etaee, Farshid, Fakhradiyev, Ildar , Fakorede, Sodiq, Farasani, Abdullah , Fareed, Mohammad , Farhana, Aisha, Faris, MoezAlIslam Ezzat Mahmoud, Farsi, Farima , Fatima, Zareen, Fazylov, Timur, Fekadu, Ginenus , Ferreira, Nuno, Fischer, Florian, Fonzo, Marco , Gadanya, Muktar A., Galali, Yaseen, Ganesh, Balasubramanian , Gangachannaiah, Shivaprakash, Gao, Dingwei, Garcia-Azorin, David, Garg, Paarth, Gautam, Rupesh K., Gaye, Bamba , Gebresilassie, Mizan Habtemichael, Gete, Kalab Yigermal , Ghadirian, Fataneh, Ghaffari, Kazem , Ghamkhar, Arin, Gharaibeh, Lobna, Ghasemi, Mohammadreza, Ghimire, Sailaja, Gil, Artyom Urievich, Gilani, Syed Abdullah , Gohari, Kimiya, Gohil, Megha Nishith , Golechha, Mahaveer, Goleij, Pouya , Golmohammadi, Melika , Goyal, Aman, Grada, Ayman, Grover, Ashna , Gu, Long, Gufue, Zenawi Hagos , Guo, Zheng, Gupta, Sapna , Gurgoglione, Filippo Luca, Haghtalab, Arian, Nam, Nguyen Hai, Hailu, Kirubel Tesfaye , Halder, Pritam, Hamdy, Nadia M., Hamidi, Hossein , Hamidi, Samer, Hamoudi, Rifat, Harsini, Sara, Hasnain, Md Saquib , Hassan, Ikrama, Hassan, Nageeb, Hassan, Treska S , Ahmed, Omed Hassan , Hebert, Jeffrey J., Helmy, Yosra A. , Hiraike, Yuta, Holla, Ramesh, Hoseinzadeh, Mehdi, Hostiuc, Mihaela , Hostiuc, Sorin, Hotwani, Priya, Hu, Yifei, Huang, Junjie, Huang, Yu-Song, Hushmandi, Kiavash, Hussein, Dursa, Hussein, Mohammed Asif , Ibrahim, Ismail A., Ibrayeva, Anel, Ikiroma, Adalia , Ikram, Jibran, Ilic, Irena M., Imam, Mohammad Tarique , Imani, Masoud, Imodoye, Sikiru Opeyemi, Imoh, Lucius Chidiebere , Ionescu, Andreea Iuliana, Ionescu, Radu Tudor, Iqhrammullah, Muhammad, Ishaqui, Azfar Athar, Islek, Duygu , ISMAIL, NAHLAH ELKUDSSIAH, Ismoldayev, Yerlan, Iwagami, Masao , Iyer, Mahalaxmi, Izquierdo-Condoy, Juan S.S., Jafari-Khounigh, Ali , Jahanshahi, Ali, Jahrami, Haitham , Jakovljevic, Mihajlo, Jamal, Armaan, Jamali, Navid, Jamaluddin, Jazlan , Jamshidi, Masoud, Jansen, Robin , Jarrahi, Esmaeil , Javaid, Syed Sarmad , Jawaid, Talha, JEBASINGH, FELIX, Jemal, Mohammed, Ji, Zixiang , Jibat, Nathan T., Jin, Wenyi , Jokar, Mohammad, Joseph, Nitin, Raj, Jesu Vijay Sheldon Joseph Michael, Joshi, Krupal, Joshua, Charity Ehimwenma, Jung, Sang-Hyuk, K, Vaishali, Kadir, Dler Hussein , Kahe, Farima, Kalani, Rizwan, Kalra, Sanjay, Kamenova, Saltanat, Kamorudeen, Ramat T., Kamyshnyi, Oleksandr, Kansal, Subham, Kantar, Rami S., Kar, Debasish , Karakasis, Paschalis, Karimi, Aliasghar, Behnagh, Arman Karimi , Karun, Sadanand , Kazemian, Sina, Kesse-Guyot, Emmanuelle, Khaleel, Anas, Khalid, Nauman, Khalid, Sidra, Khalil, Anees Ahmed , Khan, Ajmal, Khan, Md Abdullah Saeed, Khan, Moien AB, Khan, Muhammad Hamza , Khan, Serab, Khan, Sumaiya, Khan, Yusuf S. , Kheirallah, Khalid A, Khoshvaght, Samira, Khosravi, Sepehr, Kim, Hye Jun, Kim, Kwanghyun, Kisa, Adnan, Kishore, Ladli, Kokkorakis, Michail, Kondybayeva, Aida, Krishan, Kewal, Kua, Chong-Han, Kuddus, Mohammed, Kulimbet, Mukhtar , Kulkarni, Vishnutheertha, Kumar, Dewesh , Kumar, Nitesh, Kumar, Sanjay Kirshan, Kunutsor, Setor K., Kurpad, Krishna Prasad , Kusuma, Dian, Lahariya, Chandrakant, Lai, Daphne Teck Ching , Lai, Hanpeng , Lajunen, Timo, Lakanova, Balzhan, Lallukka, Tea, Larsson, Anders O., Le, Duc Tin , Le, Thao T. , Le, Thoa, Le, Trang Thi Bich , Ledda, Caterina, Lee, Hayeon, Lee, Sang-woong, Lee, Sergey Vadimovich, Lee, Seung Won, Leivaditis, Vasileios, Lema, Gebretsadik Kiros , Lemma, Dawit Alemu, Lenjisa, Jimma, Lewis, Mitchelle Shilpa , Li, Chengfeng , Li, Xingang , Li, Yongze, Lim, Lee-Ling, Lindholm, Daniel , Liu, Haipeng , Liu, Xianliang, Liu, Xuefeng, Liu, Yubo, Livingstone, Katherine M., Llanaj, Erand , Lokunarangoda, Niroshan Chandrajith, López-Gil, José Francisco, Lui, Pauline Po Yee, Luo, Peng, Lv, Lei, Lytvyak, Ellina, Ma, Kevin Sheng-Kai, Mabrok, Mahmoud, Machoy-Rakoczy, Monika , Madinehzad, Seyed Ataollah , Maffia, Pasquale, Gomez, Javier A. Magaña, Mahmood, Nozad Hussein, Malik, Md. Zubbair, Malta, Deborah Carvalho, MAMAND, DOSTE RASHID, Maniya, Muhammad Talha, Mansoor, Farheen, Mansourian, Marjan, Manzoor, Shaista, Marghani, Basma Hamed, Martinez-Piedra, Ramon, Martini, Santi, Martorell, Miquel, März, Winfried, Marzouk, Sammer, Masi, Stefano, Masrouri, Soroush , Maude, Richard J. , Mavrovounis, Georgios, McPhail, Steven M., Mendoza, Walter, Menezes, Ritesh G., Mengistie, Emiru Ayalew, Menon, Tara P., Mestrovic, Tomislav, Mettananda, Chamila Dinushi Kukulege, Metwally, Mohamed M.M., Jonasson, Junmei Miao , Mikrajab, Muhammad Agus Naufal, Minhas, Abdul Mannan Khan, Mirrakhimov, Erkin M., Mitra, Sayan , Mitra, Tridip, Modi, Dhruti, Mohamed, Mona Gamal, Ahmed, Khabab Abbasher Hussien Mohamed, Mohammad, Ameen Mosa , Mohammadi, Saeed, Mohammed, Omer, Mohan, Syam , Molla, Tewodros Shibabaw, Molokhia, Mariam, Moni, Mohammad Ali, Namin, Sara Montazeri , Morovvati, Mahdis, Heris, Reza Mosaddeghi, Motappa, Rohith, Mousavi, Seyed Ahmad , Kiasary, Seyed Mohamad Sadegh Mousavi, Yousefi, Kimia Mozahheb , Mubarik, Sumaira, Munkhsaikhan, Yanjinlkham, Musa, Sani, Mwita, Julius C., Nabipoorashrafi, SeyedAli, Nagarajan, Ahamarshan Jayaraman , Naik, Ganesh R., Naik, Hiten, Nainu, Firzan, Nartey, Yvonne , Nassar, Mahmoud, Natto, Zuhair S., Naureen, Zakira, Nawaiseh, Hala Khaled, Nayak, Biswa Prakash, Nayak, Vinod C., Nazari, Mojdeh, Ndakotsu, Andrew , Nega, Amanuel Tebabal , Nega, Mulata H., Negash, Abigia Ashenafi, Negoi, Ionut, Nguyễn, Cao Duy, Nguyen, Cuong Tat , Nguyen, Hau Thi Hien, Nguyen, Nghia Phu , Nguyen, Phat Tuan , Nguyen, Van Thanh, Niazi, Robina Khan, Nomura, Shuhei , Noreen, Mamoona , Nawsherwan, Noubiap, Jean Jacques, Nugen, Fred, Nur, Aqsha, Odediji, Saheed Adeyinka, Ogunmodede, O.S., Ojedoyin, Olusegun Olatunji , Ojo, Oluwafemi Adeleke , Okati-Aliabad, Hassan, Oliveira, Gláucia Maria Moraes, Olorukooba, Abdulhakeem Abayomi, Ong, Qi Chwen, Orru, H, Ortiz, A., Ortiz-Prado, Esteban, Osborne, Augustus, Osei, George Nkrumah , Ostrominski, John W. , Oumer, Abdu, Ouyahia, Amel, Owolabi, Mayowa O., Oyebola, Kolapo, Ozsahin, Ilker, Anand, Mahesh Padukudru, Palicz, Tamás , Panda, Sujogya Kumar , Pandi-Perumal, Seithikurippu R., Panos, Georgios D., Papadimopoulos, Ilias, Parija, Pragyan Paramita , Parikh, Romil R., Pascucci, Eleonora, Pasovic, Maja , Passera, Roberto, Patel, Mitesh, Patel, Niki Rut, Patel, Satyananda, Patil, Ashlesh, Patil, Shankargouda, Patoulias, Dimitrios, Pattnaik, Snigdha, Toroudi, Hamidreza Pazoki, Pekarcikova, Jarmila, Peprah, Prince, Pereira, Gavin, Pirera, Edoardo , Plotnikov, Evgenii, Poluru, Ramesh, Prasad, Manya, Prashant, Akila, Prates, Elton Junio Sady, Pugliese, Nicola Riccardo, Puvvula, Jagadeesh, Qi, Xiang, Qureshi, Ali, Radhakrishnan, Venkatraman, Raghav, Pankaja, Raghav, Yashpal Singh Raghav, Raghuveer, Pracheth , Rahim, Fakher , Rahim, Hawbash Mohammed-Amin, Rahimi, Sajjad, Rahman, Fryad Majeed, Rahman, M Sajjadur , Rahman, Mohammad Hifz Ur, Rahman, Mosiur, Rajendran, Judah, Rajput, Prashant, Ramasamy, Chitra, Ramasamy, Shakthi Kumaran, Rao, Asad Gul , Rao, Mithun , Rao, Sowmya J, Rasouli-Saravani, Ashkan, Rath, Shree, Rathi, Isha, Rawaf, David Laith , Rawaf, Salman, Reddy, Murali Mohan Rama Krishna, Rezaei, Mina, Rezaei, Nazila, Rezaeian, Mohsen , Rodriguez, Jefferson Antonio Buendia, Roever, Leonardo, Ross, Allen Guy Patrick, Rubeshkumar, Polani, Rwegerera, Godfrey Mutashambara , Saad, Aly M. A., Sabet, Cameron John, Sadarangani, Kabir P., Rafiei, Seyed Kiarash Sadat, Sadeghi, Ehsan, Sadeghi, Erfan, Sadeghi, Masoumeh, Sadek, Bassem, Sadek, Mustafa, Sadr, Hossein, Saeb, Mohammad Reza, Saeed, Umar, Saeedi, Maryam , Safiullah, Muhammad , Sahebkar, Amirhossein, Sajadi, S Mohammad, Saleh, Mohamed A., Salehi, Mahdi , Salimi, Sohrab, Samargandy, Saad, Samy, Abdallah M., Saravanan, Aswini , Sarfo, Jacob Owusu, Sarode, Gargi Sachin, Sarode, Sachin C., Sathian, Brijesh, Far, Mehrdad Savabi, Schlaich, Markus P., Schuermans, Art, Sejben, Anita, Semreen, Mohammad H., Senol, Yigit Can, Sessa, Francesco, Sewor, Christian , Seylani, Allen, Shahrahmani, Fatemeh, Shahwan, Moyad Jamal, Sham, Sunder, Shan, Dan, Sharifan, Amin , Sharma, Kamal, Sharma, Ravi Kumar, Sharma, Ujjawal , Shehzadi, Somia , Shetty, Mahabalesh, Shetty, Pavanchand H, Shi, Fanchao , Shi, Huizhong , Shi, Yongfeng, Shiri, Rahman , Shittu, Aminu, Shiue, Ivy, Shoaib, Ambreen, Shool, Sina, Shorofi, Seyed Afshin, Shuval, Kerem, Sia, Ching-Hui, Silva, Luís Manuel Lopes Rodrigues, Singh, Amit, Singh, Baljinder, Singh, Harmanjit, Singh, Harpreet, Singh, Lucky, Singh, Paramdeep, Singh, Siddharth , Singh, Sunil Kumar, Singh, Surjit, Singh, Vanshika , Sinha, Mukesh Kumar, Skryabin, Valentin Yurievich, Sokhal, Balamrit Singh , Sood, Prashant , Soraneh, Soroush , Sorensen, Reed J D , Srivastav, Prateek , Stanikzai, Muhammad Haroon , Starodubova, Antonina V., Stubbs, Peter, Suhag, Alisha, Sulaiman, Sahabi K., Odidi, Muritala Suleiman, Sulistiyorini, Desy , Sun, Jing , Sun, Zhong, Szarpak, Lukasz, Ty, Sree Sudha, Damavandi, Payam Tabaee, Tabatabaei, Seyyed Mohammad, Tabatabai, Shima, Tagiisuran, Balamurugan, Ali, Eman Taha Osman, Soodejani, Moslem Taheri, Taiba, Jabeen, Tajabadi, Shima, Talic, Stella, Talukder, Ashis, Adugna, Dessalegn Tamiru, Tampa, Mircea, Tan, Jianye, Tanabayeva, Dariga, Tanashat, Mohammad , Tang, Jiahao , Tantisattamo, Ekamol, Tariq, Saba, Temsah, Reem, Teramoto, Masayuki, Tesfamariam, Wegen Beyene , Tewari, Jay , Thakar, Vidhi, Thangavelu, Lakshmi, Tharwat, Ismaeel, Thiruvengadam, Muthu , Thomas, Nikhil Kenny, Ticoalu, Jansje Henny Vera, Tiwari, Krishna, Tleshev, Madi, Tonelli, Marcello, Topór-Mądry, Roman , Touvier, Mathilde, Tovani-Palone, Marcos Roberto, Tran, An Thien, Tran, Thang Huu, Duc, Nguyen Tran Minh , Tricò, Domenico , Tse, Gary, Tseriotis, Vasilis-Spyridon, Tualeka, Abdul Rohim , Tye, Sok Cin , Ullah, Riaz, Umair, Muhammad, Umar, Lawan , Ozsahin, Dilber Uzun, Uzunçıbuk, Hande, Vaithinathan, Asokan Govindaraj , Vakili, Omid , Eynde, Jef Van den, Varghese, Joe, Vellingiri, Balachandar, Verma, Poonam, Villalobos-Daniel, Victor E., Vlassov, Vasily, Wang, Nelson, Wang, Qingzhi, Wang, Wanzhou, Wang, Wei, Wang, Yanzhong, Wang, Zhihua, Wani, Tanveer A.A., Wei, Melissa Y., Weintraub, Robert G., Wibowo, Yohanes Cakrapradipta, Wickramasinghe, Dakshitha Praneeth, Wickramasinghe, Nuwan Darshana, Witts, William Kwame , Wonde, Tewodros Eshete , Wongsin, Utoomporn , Wu, Peng, Xiao, Guangqin, Xie, Wanqing , Xu, Suowen, Xu, Wanqing, Yadav, Vikas , Yahoo, Saba, Yang, Hanwen, Yano, Yuichiro , Yao, Haiqiang , Yarahmadi, Amir, Yin, Dehui , Yismaw, Yazachew Engida, Yon, Dong Keon, Yu, Chuanhua, Yu, Elaine A., Yu, Hairui , Yu, Yong , Yuan, Quan, Zafar, Mubashir , Zaghampour, Manijeh, Zamora, Nelson, Zanghì, Aurora , Zargar, Seema , Zeariya, Mohammed G M, Zeru, Eyael M, Zhang, Beijian, Zhang, Hanyu, Zhang, Julio Min Fei, Zhang, Yunquan, Zhang, Zhichang, Zhanuzakov, Murat , Zhao, Zhongyi, Zheng, Ming‐Hua , Zhong, Anthony , Zhong, Claire Chenwen, Zhou, Hao, Zhou, Jiayan, Zhou, Xiao-Dong, Zhu, Zhengyang , Zhumagaliuly, Abzal, Zitoun, Osama A. , Zoghi, Ghazal , Zoromba, Mohamed Ali, Zumla, Alimuddin, Zyoud, Sa’ed H., Hay, Simon I., Mokdad, Ali H., Murray, Christopher J. L., Roth, Gregory A., Sun, Zhong , Hay, Simon I , Roever, Leonardo , Krishan, Kewal , Moni, Mohammad Ali , Buendía, Jefferson Antonio , Badar, Muhammad , Wickramasinghe, Nuwan Darshana , Nassar, Mahmoud , Dewan, Syed Masudur Rahman , Naik, Ganesh R. , Wang, Yanzhong , Rath, Shree , Karakasis, Paschalis , Zheng, Ming-Hua , Taiba, Jabeen , Razo, Christian , DeCleene, Nicole K., LeGrand, Kate E , Abaraogu, Ukachukwu Okoroafor , ElHafeez, Samar Abd , Abdelmasseh, Michael , Abdelnabi, Mahmoud , Abd‐Elsalam, Sherief , Elshenawy, Rasha Abdelsalam , Abdelwahab, Siddig İbrahim , Abdolizadeh, Ali , Abdollahi, Arash, Abdoun, Meriem , Abdrabou, Mostafa M. , Abdulah, Deldar Morad , Abdullahi, Auwal , Shenkut, Melese, Abiodun, Olugbenga Olusola , Abiodun, Olumide A , Abohashem, Shady , Abtahi, Dariush , Farha, Rana Kamal Abu , Abubakar, Bilyaminu , Abuhelwa, Ahmad Y. , Abukhadijah, Hana J , Aburuz, Salahdein , Adamu, Nuhu Lawan , Adane, Mesafint Molla , Addo, Isaac Yeboah , Adedokun, Kamoru Ademola , Adekola, Saheed Ayodeji, Adesina, Miracle Ayomikun , Adisu, Molalign Aligaz , Adnan, Mohd , Afoakwah, Clifford , Afolabi, Aanuoluwapo Adeyimika, Afrifa‐Yamoah, Ebenezer , Afzal, Saira , Agordoh, Percival Delali , Ahmad, Aqeel , Ahmad, Khabir , Ahmad, Sajjad , Ahmed, Gasha Salih, Ahmed, Nesredin , Ajami, Marjan , Akhtar, Muhammad Nadeem , Akindele, Mukadas Oyeniran , Akkaif, Mohammed Ahmed , Akyea, Ralph Kwame , Zoubi, Mohammad Ahmmad Mahmoud Al, Alalwan, Tariq A. , Al‐Aly, Ziyad , Al-Amri, Issa Sulaiman , Alanzi, Turki Matar Khalaf, Al-Ashwal, Fahmi Y. , Al‐Azayzih, Ahmad , Al-Azzam, Sayer , Al-Bashaireh, Ahmad M. , ALBashtawy, Mohammed , Aleidi, Shereen M. , Algahtani, Fahad D. , AlHabib, Khalid F. , Ali, Abid , Ali, Asgar , Ali, Bassam R. , Al‐Iede, Montaha , Alif, Sheikh Mohammad , Alipour, Morteza, Al‐Jabi, Samah W. , Aljunid, Syed Mohamed , Alkubati, Sameer Abdulmalik , Almagharbeh, Wesam Taher , Almahmeed, Wael , Almazan, Joseph Uy , Alniss, Hasan Yaser , Alomari, Mahmoud A. , Alotaibi, Haifa F. , Alqahtani, Saleh A. , Alqudimat, Mohammad R. , Al-Qudimat, Ahmad Rajeh , Al‐Raddadi, Rajaa , Alsbou, Mohammed , Alshahrani, Najim Zafer , Al-Shami, Ali Salman , Altaf, Awais , Althobiani, Malik A , Alwafi, Hassan , Al‐Worafi, Yaser Mohammed , Aly, Hany Z. , Al‐Zalabani, Abdulmohsen H. , Alzoubi, Abdallah , Alzoubi, Karem Hasan , Amafah, Joy, Amin, Amr , Amini, Saeed, Amini‐Salehi, Ehsan , Amusa, Ganiyu , Ang, Song Peng , Anieto, Ebuka Miracle , Anil, Abhishek , Anjana, Dr. Prapti, Anvari, Saeid, Appati, Walter , Arabloo, Jalal , Arafat, Mosab , Areda, Demelash, Arefnezhad, Reza , Torre, Jorge Arias de la, Aripov, Timur , Arockiaraj, Jesu , Asdaq, Syed Mohammed Basheeruddin , Ashraf, Syed Amir , Ashraf, Tahira , Ataç, Ömer , Athar, Mohammad , Athari, Seyyed Shamsadin , Aurangzeb, Khursheed , Awan, Sana Javaid , Awol, Kemal Lemnuro, Awotidebe, Adedapo Wasiu , Aylı, Berrak Itır , Azarboo, Alireza , Aziz, Sadat Abdulla , Azzolino, Domenico , Babu, Abraham Samuel , Babu, Giridhara R. , Badiye, Ashish , Baghlaf, Khlood K , Baig, Atif Amin , Bakhshali, Mohamad Amin , Banach, Maciej , Banik, Palash Chandra , Barqawi, Hiba Jawdat , Barrow, Amadou , Barua, Lingkan , Bashir, Shahid , Bashiri, Azadeh , Bastan, Mohammad‐Mahdi , Bayih, Mulat Tirfie , Beeraka, Narasimha Murthy , Begum, Tahmina , Behera, Priyamadhaba , Behnam, Babak , Ramírez, Diana Fernanda Bejarano , Belo, Luı́s , Berihun, Abiye Assefa , Bhattacharjee, Priyadarshini , Bhatti, Gurjit Kaur , Bhatti, Jasvinder Singh , Biswas, Atanu , Biswas, Bijit , Bizzozero‐Peroni, Bruno , Bodur, Mahmut , Bogale, Sitotaw Kerie , Bohn, Lucimére , Boloor, Archith , Carvajal, Alejandro Botero , Boudalia, Sofiane , Bugiardini, Raffaele , Busch, Felix , Bustanji, Yasser, Campos, Luciana Aparecida , Catapano, Alberico Luigi , Cegolon, Luca , Cenko, Edina , Cerin, Ester , Chakraborty, Chiranjib , Chandika, Rama Mohan , Chandrasekar, Eeshwar K , Chandrasekaran, Baskaran , Chattu, Vijay Kumar , Chaudhary, Anis Ahmad , Chaudhuri, Sirshendu , Cheema, Asad Ali Ahmed , Chichagi, Fatemeh , Ching, Patrick R , Cho, William C.S., Choi, Dong‐Woo , Chong, Bryan , Chopra, Deepti , Chopra, Hitesh , Choudhari, Sonali Gajanan , Chu, Dinh‐Toi , Chukwu, Chidozie Williams , Chung, Sheng‐Chia , Chung, S. Y. , Cicero, Arrigo F.G. , Cosma, Claudia , Criqui, Michael H. , Dadras, Omid , Dai, Xiaochen , Dai, Zhaoli , Dalakoti, Mayank , D’Amico, Emanuele , Tesfa, Endalamaw , Danpanichkul, Pojsakorn , Darcho, Samuel Demissie , Davletov, Dimash , Davletov, Kairat , Dejenie, Tadesse Asmamaw , Bo’, Cristian Del , Delgado‐Enciso, Iván , Denova‐Gutiérrez, Edgar , Dergaa, Ismail , Dervišević, Emina , Devegowda, Devananda , Dewan, Syed Masudur Rahman , Dhimal, Meghnath , Dhungel, Bibha , Do, Thanh Chi, Phuong, Thao Huynh, Doshi, Ojas Prakashbhai , Doshi, Rajkumar , Dourado, Paulo Magno Martins , Dowou, Robert Kokou , Du, Mi , Duncan, Bruce Bartholow , Durães, André Rodrigues , Ebohon, Osamudiamen , Eftekhari, Behrad , Eladl, Mohamed Ahmed , Eldaboush, Ahmed , Elgendy, Islam Y. , Elhadi, Muhammed , El‐Huneidi, Waseem , Elmonem, Mohamed A. , Elmoselhi, Adel B. , Fabin, Natalia , Fadaka, Adewale Oluwaseun , Fagbamigbe, Adeniyi Francis , Fakorede, Sodiq , Fatima, Zareen , Fayaz, Mohammad , Fazylov, Timur, Fernández‐Jiménez, Rodrigo , Fischer, Florian, Fogacci, Federica , Foschi, Matteo , Gadanya, Muktar A., Gajdács, Márió , Galali, Yaseen , Ganesan, Balasankar , Gangachannaiah, Shivaprakash , Gašević, Danijela , Habtemichael, Mizan , Getacher, Lemma , Jolfayi, Amir Ghaffari , Ghamkhar, Arin, Ghazy, Ramy Mohamed , Ghimire, Sailaja, Ghith, Nermin , Gil, Artyom , Gill, Paramjit Singh , Gnedovskaya, Elena V. , Goh, Lay Hoon , Gohari, Kimiya, Golechha, Mahaveer , Goulart, Alessandra C. , Goyal, Aman , Grada, Ayman , Gu, Long , Gubari, Mohammed Ibrahim Mohialdeen , Guha, Avirup , Gunawardane, Damitha Asanga , Gupta, Rajeev , Gurgoglione, Filippo Luca , Guzmán-Esquivel, José , Guzmán-Muñoz, Eduardo , Haghtalab, Arian , Halder, Pritam , Hamdy, Nadia Μ. , Hammad, Eman A. , Hanif, Asif , Hanifi, Nasrin , Hankey, Graeme J. , Harsini, Sara , Hartmann, Phillipp , Hasan, Ikramul , Hashempur, Mohammad Hashem , Hassan, Amr , Hassan, Ibrahim Nagmeldin , Hayat, Khezar , Hezam, Kamal , Hiraike, Yuta , Holla, Ramesh , Hostiuc, Sorin , Htay, Mila Nu Nu , Huang, Junjie, Hushmandi, Kiavash , Hwang, Bing‐Fang , Ibitoye, Segun Emmanuel , Ibrahim, Khalid S. , Ibrayeva, Anel , Ikram, Jibran, Ilesanmi, Olayinka Stephen , Ilić, Irena , Ilić, Milena , Imodoye, Sikiru O. , Inbaraj, Leeberk Raja , Ionescu, Radu Tudor, Iqhrammullah, Muhammad , Irham, Lalu Muhammad , Ishaqui, Azfar Athar , Ismail, Nahlah Elkudssiah , Ismoldayev, Yerlan, Isola, Gaetano , Izquierdo‐Condoy, Juan S. , Jacob, Jaison , Jahanshahi, Ali , Jamal, Armaan , Jamali, Navid , James, Jerin , Jamshidi, Masoud , Jawaid, Talha, Jayasinghe, Yovanthi Anurangi , Jemal, Mohammed , Jeong, Seogsong , Jeswani, Bijay Mukesh , Jibat, Nathan Tolemariam , Jokar, Mohammad , Joó, Tamás , Joseph, Akaninyene Paul , Joseph, Mickaël Antoine , Joseph, Nitin , Joshi, Krupal , Jürisson, Mikk , K, Vaishali , Kakkar, Ashish Kumar , Kalani, Rizwan , Kalavani, Khalil , Kalra, Sanjay , Kamorudeen, Ramat T. , Kamyshnyi, Oleksandr , Kanaan, Saddam Fuad , Kanmodi, Kehinde Kazeem , Kantar, Rami S. , Kapoor, Neeti , Karajizadeh, Mehrdad , Karakasis, Paschalis , Karasneh, Reema A. , Kashoo, Faizan , Kashyap, Manoj Kumar , Kausar, Mohd Adnan , Kazemian, Sina , Kebede, Yabets Tesfaye , Kesse‐Guyot, Emmanuelle , Khademi, Reza , Khader, Yousef , Khajuria, Himanshu , Khaleel, Anas , Khalid, Sidra , Khalili, Anita , Khalili, Pantea , Khan, Maseer , Khan, Mohammad Idreesh , Khasbage, Sameer Uttamaro , Khatatbeh, Moawiah Mohammad , Khosla, Pavan , Khosravi, Sepehr , Kimokoti, Ruth W , Kısa, Adnan , Kishore, Ladli , Kivimäki, Mika , Kokkorakis, Michail , Kolahi, Ali‐Asghar , Kompani, Farzad , Kondybayeva, Аida , Korzh, Oleksii , Kostev, Karel , Laxminarayana, Sindhura Lakshmi Koulmane , Kua, Chong-Han , Kuddus, Mohammed , Kumar, Chandan , Kumar, G Anil , Kumar, Jogender , Kumar, Laksh , Kundu, Amartya , Kundu, Satyajit , Kunutsor, Setor K. , Kurniasari, Maria Dyah , Kytö, Ville , Lahariya, Chandrakant , Lakanova, Balzhan, Lantos, Tamás , Larebo, Yilma Markos , Lasrado, Savita , Lee�, HwaMin , Lee, Wei‐Chen , Leivaditis, Vasileios , Lenjisa, Jimma Likisa , Li, Ming‐Chieh , Li, Qiang , Li, Shaojie , Lim, Lee-Ling , Lodhi, Madeeha Shahzad , Lokunarangoda, Niroshan Chandrajith , López-Gil, José Francisco , Lorkowski, Stefan , Lucchetti, Giancarlo , Lui, Pauline Po Yee , Lv, Lei , Lytvyak, Ellina , Amin, Hawraz Ibrahim M. , Maffia, Pasquale , Magaña‐Gómez, Javier A. , Mahalleh, Mehrdad , Malik, Ahmad Azam , Malik, Tabarak , Malta, Déborah Carvalho , Mamand, Doste R. , Maniya, Muhammad Talha , Mannethodi, Kamaruddeen , Mansoor, Farheen, Mansourian, Marjan , Maqsood, Kaleem , Marateb, Hamid Reza , Marghani, Basma H. , Marino, Mirko , Martínez, Ramón , Martini, Daniela , Martini, Santi , Martorell, Miquel , März, Winfried , Marzouk, Sammer , Masi, Stefano , Mathur, Neeta , Matozinhos, Fernanda Penido , Mattiello, Rita , Mavrovounis, Georgios , McPhail, Steven , Mehto, Subhash , Meles, Hadush Negash , Menezes, Godfred Antony , Menon, Tara Pattilachan, Mensah, George A. , Merlino, Giovanni , Meštrović, Tomislav , Mettananda, Chamila Dinushi Kukulege , Mettananda, Sachith , Metwally, Mohamed M M, Mikrajab, Muhammad Agus, Minhas, Abdul Mannan Khan , Mittal, Madhukar , Mohamed, Nouh Saad , Ahmed, Khabab Abbasher Hussien Mohamed , Mohammad, Taj , Mohammadi, Abbas , Mohammadi, Mokhtar , Mohammadian-Hafshejani, Abdollah , Mohsen, Yazan , Shibabaw, Tewodros , Molokhia, Mariam , Monazzami, Amirabbas , Ghalibaf, AmirAli Moodi , Morovvati, Mahdis, Motappa, Rohith , Mozafar, Mehrdad , Mubarik, Sumaira , Muhammad, Jibran Sualeh , Munkhsaikhan, Yanjinlkham, Munshi, Anjana , Musa, Sani , Muthu, Sathish , Mwita, Julius Chacha , Myung, Woojae , Nainu, Firzan , Nargus, Shumaila , Nasrollahizadeh, Amir , Nassar, Mahmoud, Nauman, Javaid , Navaratna, Samidi Nirasha Kumari , Nawaiseh, Hala K. , Nayak, Biswa Prakash, Nega, Mulata Haile , Negash, Abigia Ashenafi , Negoi, Ionuţ , Abadi, Reza Nejad Shahrokh , Nematollahi, Mohammad Hadi , Nieddu, Luciano , Nketia, Richmond , Noubiap, Jean Jacques , Nri-Ezedi, Chisom Adaobi , Ntsekhe, Mpiko , Nugen, Fred , Oancea, Bogdan , Odat, Ramez M. , Oddi, Fabio Massimo , Oh, In‐Hwan , Okekunle, Akinkunmi Paul , Okonji, Osaretin Christabel , Olorukooba, Abdulhakeem Abayomi , Ong, Qi Chwen , Ordak, Michał , Orscelik, Atakan , Ortiz‐Prado, Esteban , Osuagwu, Uchechukwu Levi , Oumer, Abdu , Ouyahia, Amel , Özşahin, İlker , Padrón‐Monedero, Alicia , Padubidri, Jagadish Rao , Panos, Georgios D. , Papa, Mario Virgilio , Pardhan, Shahina , Passera, Roberto , Patel, Kunal Nitinkumar , Patel, Neel Navinkumar , Patel, Satyananda, Patil, Shankargouda, Patoulias, Dimitrios , Pattnaik, Snigdha, Toroudi, Hamidreza Pazoki, Pekarčíková, Jarmila , Peprah, Prince , Pereira, Gavin, Perico, Norberto , Perna, Simone , Petermann‐Rocha, Fanny , Pirnejad, Habibollah , Plotnikov, Evgenii, Poddighe, Dimitri , Poluru, Ramesh , Porntaveetus, Thantrira , Pradhan, Pranil Man Singh , Prasad, Manya , Prashant, Akila , Pugliese, Nicola Riccardo , Puvvula, Jagadeesh , Qiu, Jia-Yong , Radhakrishnan, Venkatraman, Raghav, Pankaja Raghav, Rahamon, Sheu Kadiri , Rahim, Hawbash Mohammed-Amin , Rahimi, Sajjad , Rahman, Muhammad Aziz , Raj, Jeffrey Pradeep , Raja, Adarsh , Rajendran, Judah , Rajput, Prashant , Ramadan, Mahmoud M. , Ramasamy, Chitra, Ramasamy, Shakthi Kumaran, Rashedi, Vahid , Rasouli‐Saravani, Ashkan , Rath, Shree , Rathi, Isha , Rathish, Devarajan , Rauniyar, Santosh Kumar , Rawassizadeh, Reza , Ray, Asit , Redwan, Elrashdy M , Rehman, Najeeb Ur , Remuzzi, Giuseppe , Rezaei, Nazila , Romadlon, Debby Syahru , Romoli, Michele , Rony, Moustaq Karim Khan , Ross, Allen Guy , Roy, Sharmistha , Roy, Shubhanjali , Russo, Michele , Saber-Ayad, Maha Mohamed , Sabet, Cameron John , Sadarangani, Kabir P. , Rafiei, Seyed Kiarash Sadat , Saddique, Muhammad Nabeel , Sadee, Bashdar Abuzed , Sadeghi, Masoumeh , Sadek, Bassem Shaban , Sadr, Hossein, Saeb, Mohammad Reza , Saeed, Mοhd , Saeedi, Maryam , Saghazadeh, Amene , Sagoe, Dominic , Sah, Ashok Kumar , Sharif‐Askari, Fatemeh Saheb , Sahebkar, Amirhossein , Sajadi, S. Mohammad, Sajid, Mirza Rizwan , Saki, Morteza , Sakshaug, Joseph W. , Salami, Afeez Abolarinwa , Saleem, Rahman Shah Zaib , Salihu, Abubakar Tijjani , Salimi, Sohrab , Samargandy, Saad J. , Samodra, Yoseph Leonardo , Samy, Abdallah M., Sarfo, Jacob Owusu , Sarmadi, Mohammad , Sarode, Gargi Sachin , Sassano, Michele , Sathian, Brijesh , Narayanan, Mukesh Kumar Sathya , Schlaich, Markus P. , Schuermans, Art , Schwarz, Ghil , Sejben, Anita , Selvaraj, Siddharthan , Semreen, Mohammad H. , Şenol, Yiğit Can , Şerban, Dragoş , Sethi, Yashendra , Setiawan, Christianus Heru , Shahid, Samiah , Shahini, Endrit , Shahrahmani, Fatemeh, Shahwan, Moyad Jamal , Shamim, Muhammad Aaqib , Shamsi, Anas , Shan, Dan, Shanawaz, Mohd , Shannawaz, Mohammed , Sharif, Nadim , Sharma, Bhoopesh Kumar , Sharma, Bunty, Sharma, Manoj , Sharma, Vishal , Shastry, Shamee , Sheidaei, Ali , Shenoy, Rekha R. , Shimels, Tariku , Shittu, Aminu , Shoaib, Ambreen , Shool, Sina , Shrestha, Sunil , Shuval, Kerem , Sia, Ching‐Hui , Siddig, Emmanuel Edwar , Siddiqi, Ahmed Kamal , Siddiqua, Ayesha , Silva, Diego Augusto Santos , Simkhada, Padam Prasad , Singh, Amit Kumar, Singh, Baljinder, Singh, Harpreet, Singh, Jasvinder A. , Singh, Lucky, Singh, Poornima Suryanath , Singh, Puneetpal , Sinha, Mukesh Kumar , Sinha, Ratnesh , Skryabin, Valentin Yurievich , Sorrentino, Michele , Spartalis, Michael , Stachteas, Panagiotis , Владимировна, Стародубова Антонина, Straube, Sebastian , Stubbs, Peter W. , Su, Chen‐Yang , Subramaniyan, Vetriselvan , Suhag, Alisha , Sulaieva, Oksana , Sun, Jing , Swain, Chandan Kumar , Szarpak, Łukasz , Y, Sree Sudha T, Damavandi, Payam Tabaee , Tabarés‐Seisdedos, Rafael , Tabatabaeizadeh, Seyed‐Amir , Tabche, Celine , Tadele, Afework , Ali, Eman T. , Soodejani, Moslem Taheri , Tajabadi, Shima, Talic, Stella , Talukder, Ashis , Zadeh, Seyed Saeed Tamehri , Tampa, Mircea Ştefan , Tantisattamo, Ekamol , Tariku, Mengistie Kassahun , Tavangar, Seyed Mohammad , Tedla, Mebrahtu G. , Teramoto, Masayuki , Tesfu, Azimeraw Arega , Tharwat, Ismaeel, Tharwat, Samar , Thienemann, Friedrich , Tiruye, Tenaw Yimer , Tleshev, Madi, Tomo, Sojit , Tonelli, Marcello , Touvier, Mathilde , Tran, An Thien, Tran, Thang Huu, Tristan, Christopher Daniel , Tse, Gary , Tseriotis, Vasilis‐Spyridon , Udoakang, Aniefiok John , Ullah, Atta , Ullah, Saeed , Umair, Muhammad, Upadhya, Dinesh , Upadhyay, Era , Usman, Jibrin Sammani , Ozsahin, Dilber Uzun , Uzunçıbuk, Hande , Varghese, Joe , Vasankari, Tommi Juhani , Vellingiri, Balachandar , Venketasubramanian, Narayanaswamy , Verma, Akshaya Kumar , Villalobos-Daniel, Victor Eduardo , Wan, Jin‐Yi , Wang, Cong , Wang, Nelson , Wang, Shaopan , Wang, Shu , Wang, Youxin , Wani, Tanveer A. , Waqar, Ahmed Bilal , Weintraub, Robert G, Wibowo, Yohanes Cakrapradipta, Wicaksana, Anggi Lukman , Wickramasinghe, Dakshitha Praneeth , Wilandika, Angga , Xu, Site , Xu, Suowen , Xu, Xiaoyue , Yadegar, Amirhossein , Yahoo, Saba, Yamagishi, Kazumasa , Yaribeygi, Habib , Yesuf, Subah Abderehim , Yon, Dong Keon , Yonemoto, Naohiro , Yuan, Quan, Yuzbashian, Emad , Zamagni, Giulia , Zawiah, Mohammed , Zeariya, Mohammed G M, Zeru, Eyael M, Zhang, Casper J. P. , Zhong, Claire Chenwen , Zhou, Xiao-Dong, Zhumagaliuly, Abzal , Zoromba, Mohamed Ali , Zumla, Alimuddin I. , Zyoud, Ahed H. , Zyoud, Shaher H. , Mokdad, Ali H. , Murray, Christopher J. L., Roth, Gregory A., Kheirallah, Khalid Ahmed , Saad, Aly M A , Sadeghi, Erfan

Mayo Clinic

JAMA | July 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jama.2026.8628 | PMID 42525403 Get It

Importance Elevated low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for cardiovascular disease, the leading cause of premature death worldwide. Assessing the LDL-C–related burden is critical for guiding prevention and treatment strategies. Objectives To estimate the global, regional, and national burden of ischemic heart disease and ischemic stroke attributable to elevated LDL-C (relative to 35-54 mg/dL) from 1990 to 2023 and to quantify the contributions of population growth, aging, risk-deleted burden, and exposure changes to burden trends. Design, Setting, and Population This comparative risk assessment, part of the Global Burden of Disease Study 2023, estimated population-level LDL-C exposure and associated health loss in 204 countries and territories. Mean LDL-C levels were estimated using spatiotemporal gaussian process regression based on 806 studies across 161 countries. Relative risks were derived from meta-analyses of 38 randomized clinical trials. Population-attributable fractions for deaths and disability-adjusted life-years (DALYs) were estimated by age and sex for adults aged 25 years or older from 1990 to 2023, with 95% uncertainty intervals. Exposure Population-level LDL-C concentrations. Main Outcomes and Measures Population-attributable fractions, counts, and rates (all ages and age standardized per 100 000) of LDL-C–attributable deaths and DALYs from ischemic heart disease and ischemic stroke, with uncertainty intervals. Results In 2023, elevated LDL-C accounted for 3.6 million deaths (95% uncertainty interval, 2.2-5.4 million; 6.0% of global mortality) and 90.7 million DALYs (95% uncertainty interval, 58.9-123.3 million; 3.2% of DALYs). Although global all-ages rates remained stable, age-standardized death and DALY rates decreased by 45.6% and 39.5%, respectively, since 1990. In 2023, age-standardized LDL-C–attributable DALY rates were highest in Eastern Europe and lowest in high-income Asia-Pacific. One-third of the global LDL-C burden occurred in India and China. Population growth and aging drove the increasing burden, with notable regional disparities in LDL-C exposure and risk-deleted DALY rates shifting toward middle-sociodemographic settings. Conclusions and Relevance Despite declining age-standardized rates, the absolute LDL-C burden has increased since 1990 due to demographic changes and has shifted toward middle-sociodemographic countries. Measurement and surveillance gaps persist. Strengthened prevention, diagnosis, and treatment access strategies are essential to mitigate the health burden of LDL-C.
Advancing Prostate Cancer Survivorship Through Transatlantic Consortium Science: The iCCaRE Initiative
Odedina, Folakemi T. , Dronca, Roxana , Ashing, Kimlin , Kaninjing, Ernest , Rotimi, Solomon O. , Ngufor, Che , Merriweather, Arnold , Gordon, Vinessa , Asto-Flores, Emelina , Adeniji, Kayode, Agboola, Emmanuel, Aliche, Uju, Aliyu, Usman M., Ashing, Kimlin Tam, Asiedu, Gladys, Badejo, Paul, Johnson, Kim Barbel, Beckford, Patrick , Blocker, Renaldo, Bolajoko, Opeyemi, Bonner, Timethia J, Breland, Ivey, Caballero, Amanda , Carter, Rickey, Cattnell, Alex, COBRAN, Ewan, Colon-Otero, Gerardo, Copland, John A., Phd, Getachew Dagne, Campos, Opeyemi C. De, Doty, Melissa, Dronca, Roxana, Erefah, Ebenezer, Falzon, Kaila, Francis, Damian, Fudge, Michelle, Fullwood, Dottington , Gainer, Jeffery, Glaser-Boivin, Dee, Hill, Antony, Hinsom, Rakenya, Iweala, Emeka J., Kaninjing, Ernie, Kase, Adam, Knutsen, Keith, Lee, Daniel, Leyva, Sandra Casanova, Lindeman, Carolyn R., Mahin, Collisa, Maniaci, Michael, Hew, Trevanne Matthews, Hew, Trevanne R. Matthews, Melton, Jada K., Merriweather, Arnold, Mitchell, Luisa, Moore, Cassandra, Ngufor, Che, Nolan, Lucia, Odedina, Abimbola, Odedina, Folakemi, Oladoyinbo, Catherine, Olasehinde, Esther, Onyia, Abimbola F., Popoola, Ademoola, Rotimi, Solomon O., Scales, Tracie, Sledge, Hanna, Thompson-Reeves, Jade, Toye, Oluwaseyi, Duarte, Claudia Valles, Voorhis, Kaitlin Van, Waldon, Charles F., Walsh-Childers, Kim , Williams, Christopher, Willis, Floyd , Wimberly, Quincy , Yahaya, Ayinde, Yates, PhD Clayton, Yost, Kathleen, Young, Mary Ellen , Zou, Tingyu, Ashing, Kimlin Tam , Rotimi, Solomon , Odedina, Folakemi , Kaninjing, Ernest T , Ngufor, Che G , Aliche, Uju, Badejo, Paul, Blocker, Renaldo, Bolajoko, Opeyemi , Cattnell, Alex, Cobran, Ewan K. , Colon-Otero, Gerardo, Copland, John A., Francis, Damian, Fudge, Michelle , Gainer, Jeffery, Gokara, Mahesh , Hinsom, Rakenya, Iweala, Emeka J., Knutsen, Keith, Lee, Daniel, Lindeman, Carolyn R., McCall, John , Melton, Jada K., Mitchell, Luisa, Olasehinde, Esther, Popoola, Ademoola, Reynolds, Jordan , Scales, Tracie, Sledge, Hanna, Thompson-Reeves, Jade, Toye, Oluwaseyi, Duarte, Claudia Valles, Voorhis, Kaitlin Van, Waldon, Charles F., Williams, Christopher, Yost, Kathleen, Zou, Tingyu

Mayo Clinic

Cancer Research Communications | July 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/2767-9764.crc-26-0165 | PMID 42497456 Get It

Abstract Black/African American populations, globally, bear the greatest prostate cancer (CaP) burden compared to other racial/ethnic groups. Addressing CaP disparities in Black men is complex, requiring a patient-centered, community-centric and comprehensive approach. This study integrates iCCaRE Consortium findings and broader literature to address unmet needs in survivorship care. The iCCaRE Consortium implemented five complementary pilot studies using mixed-methods designs, including feasibility trials, qualitative research, and observational analyses across the United States and sub-Saharan Africa. Descriptive statistics, subgroup analyses, and qualitative thematic analyses were performed across these studies. Collectively, projects addressed multilevel determinants including social, behavioral, and biological drivers of disparities. Project 1 implemented a Virtual Reality Assistant (ViRA) across clinical and community settings, with ongoing evaluation in pragmatic trials. Project 2 showed strong patient preference for home-based cancer care. Project 3 enrolled demonstrated trends toward improved health-related quality of life. Project 4 identified key themes influencing survivorship experiences. Project 5 identified biological mechanisms linking stress, immune modulation, and symptom burden. The iCCaRE pilot projects demonstrate the feasibility and early impact of a consortium-based, transdisciplinary approach to addressing CaP disparities in Black men. These findings highlight the importance of integrating patient-centered interventions, community engagement, and biological insights to inform scalable strategies aimed at improving survivorship outcomes and advancing health equity. The iCCaRE Consortium demonstrates that a transatlantic, patient-centered, and multidisciplinary approach integrating social, clinical, and biological factors can generate scalable strategies to improve survivorship outcomes and advance equity in CaP care for Black men.
Expert Clinical Consensus on Body Surface Gastric Mapping Phenotypes for Gastroduodenal Disorders: ‘Auckland Classification’ v1.0
Varghese, Chris , Dachs, Nicky , Schamberg, Gabriel , Abell, Thomas, Al‐Haddad, Mohammad, Angeli, Timothy R. , Ayubi, Homira , Bashashati, Mohammad , Bulat, Robert, Calder, Stefan, Cederwall, Christopher Brian, Chang, Bianca W. , Cheng, Leo K. , Clarke, John, Daker, Charlotte , Du, Peng, Erickson, Jon, Eriksson, Sven, Fikree, Asma , Foong, Daphne , Fox, Mark, Goenka, Mahesh, Haidry, R, Holtman, Gerald, Hobson, Anthony , Koloski, Natasha, Kuo, Braden, Law, Mikaela, Levinthal, D., Liu, Joy , Mathur, Prateek , Moshiree, Baharak, Ngo, Catherine, Nguyen, Linda, Oblizajek, Nicholas R. , Parkman, Henry P., Podboy, Alexander, Rezaie, Ali, Simmonds, Sam , Sivakumar, Jonathan , Sirimongkolkasem, Jarongkorn , Sonu, Irene, Stocker, Abigail, Sujka, Joseph, Tack, Jan, Weinstein, Douglas, Windsor, John, Zarate‐Lopez, Natalia, Andrews, Christopher N., O'Grady, Greg, Clarke, John O. , Angeli-Gordon, Timothy R , Chang, Bianca , Cheng, Leo K , Daker, Charlotte , Ghoshal, Uday C , Hasler, W L , Ho, Vincent , Keszthelyi, Daniel , Khalsa, Sahib S , Liu, Joy J , Neshatian, Leila , Oblizajek, Nicholas R , Pandanaboyana, Sanjay , Sharma, Amol , Wang, Xiao Jing , Xu, William , Varghese, Chris , Clarke, J , Schamberg, Gabriel , Al‐Haddad, Mohammad , Ayazi, Shahin , Bulat, Robert, Calder, Stefan , Cederwall, Chris, Du, Peng , Erickson, Jonathan C. , Ghoshal, Uday C. , Hasler, William L. , Hayee, Bu , Ho, Vincent , Huang, I‐Hsuan , Khalsa, Sahib S. , Kuo, Braden , Kunkel, David C. , Law, Mikaela , Levinthal, David J. , Moshiree, Baharak , Neshatian, Leila , Parkman, Henry P. , Podboy, Alexander , Rezaie, Ali , Sonu, Irene S. , Stocker, Abigail, Sujka, Joseph , Tack, Jan , Verdonk, Charles , Wang, Xiao Jing , Wongjarupong, Nicha , Xu, William , Andrews, Christopher N. , Gharibans, Armen A.

Mayo Clinic

Neurogastroenterology & Motility | July 1, 2026 | Volume: 38 | Issue: 7 | Pages: No page available

10.1111/nmo.70377 | PMID 42381563 Get It

ABSTRACT Introduction Chronic gastroduodenal disorders remain challenging to manage, and new diagnostic approaches are needed to better delineate underlying causes and guide therapeutic decisions. Body Surface Gastric Mapping (BSGM) technologies combine high‐resolution gastric myoelectrical activity measurements with symptom and psychological profiling to provide mechanistic insights into gastric motor and sensory dysfunction. An International Working Group convened to derive the first consensus classification of BSGM phenotypes (the “Auckland Classification”). Methods A Technical Group conducted a systematic literature and clinical database review to identify objective test biomarkers and candidate disease mechanisms. Evidence was synthesized across 50 studies (primarily in gastroparesis, chronic nausea and vomiting, and functional dyspepsia), and BSGM phenotypes were mapped to existing treatment guidelines. Subsequently, iterative review and development of consensus was performed by a Consensus Group composed of international clinical experts familiar with BSGM. Eleven statements underlying the classification were then derived and circulated as a final survey to establish agreement. Results Six BSGM phenotypes were endorsed: three defined by myoelectrical abnormalities (Dysrhythmic, High Frequency, and Low Meal Response) and three by characteristic symptom associations (Sensorimotor, Continuous, and Delayed Onset Symptoms). Published studies plausibly linked these phenotypes to mechanisms including interstitial cell of Cajal depletion, vagal impairment, hypomotility, visceral hypersensitivity, gut‐brain dysregulation, and small bowel dysfunction. Phenotypes were also mapped to existing mechanism‐based treatment guidelines. Ten out of the eleven statements had > 80% agreement. Conclusions The Auckland Classification, derived by international consensus, presents a structured framework for BSGM‐defined patient phenotypes. Evidence and mechanism‐based treatment options are suggested for each phenotype to provide a foundation for research, further validation, and a pathway for integrating BSGM into clinical care.
Real-World Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Treatment Delivery, Immune Reconstitution, and Cardiac Monitoring During High-Dose IL-2
Aboelatta, Mohamed A. , Zarka, Jabra , Tchatchua, Nika , Aboelatta, Noureldin A., Johnson, Jeffrey , Jakub, James W. , Desroches, Justin , Wilson-Miller, Justine, Tabiim, Anthony Jagri , Behl, Deepti , Montane, Heather N. , Kottschade, Lisa A. , Dimou, Anastasios , Block, M. , Heath, Elisabeth I. , Doonan, Bently, Seetharam, ­Mahesh , Molina, Julian R. , Charnin, Jonathan E. , Gill, Paula, Lin, Yi, Baral, Binav , Markovic, Svetomir N., Dudek, Arkadiusz Z. , Johnson, Jeffrey E , Tabiim, Anthony , Jakub, James W , Dimou, Anastasios , Montane, Heather N , Dudek, Arkadiusz Z , Zarka, Jabra G , Tchatchua, Nika , Wilson-Miller, Justine L., Doonan, Bently P. , Markovic, Svetomir N.

Mayo Clinic

Current Oncology | June 24, 2026 | Volume: 33 | Issue: 7 | Pages: 379

10.3390/curroncol33070379 | PMID 42505181 Get It

Background/Objectives: Tumor-infiltrating lymphocyte (TIL) therapy is an important option for patients with metastatic melanoma progressing after standard systemic therapy, but real-world data on treatment delivery, toxicity monitoring, and immune recovery remain limited. We evaluated clinical outcomes, treatment tolerance, immune reconstitution, and cardiac biomarker dynamics across three Mayo Clinic sites. Methods: We retrospectively analyzed adults with metastatic melanoma who received lymphodepleting chemotherapy followed by TIL infusion and high-dose interleukin-2 (IL-2) between April 2024 and December 2025. Clinical outcomes, treatment delivery, and adverse events were assessed. Longitudinal immune monitoring included CD4 and CD8 T-cell counts, CD4:CD8 ratio, and immunoglobulin G (IgG) at baseline and follow-up. In a prespecified cardiac sub-cohort, high-sensitivity troponin (hs-Tn) was measured during IL-2 administration to evaluate associations with cardiac events and IL-2 interruption. Results: Thirty-six patients underwent TIL infusion. The objective response rate was 50.0%, including complete responses in 13.9%, and the disease control rate was 72.2%. Median progression-free survival was 3.61 months, and median overall survival was 12.94 months. M1d disease was associated with inferior overall survival on univariable analysis (HR 6.55, 95% CI 2.03–21.17; p = 0.002), with attenuation after multivariable adjustment. Receipt of ≥3 IL-2 doses was associated with longer overall survival on univariable analysis (HR 0.20, 95% CI 0.06–0.64; p = 0.007), but this association also attenuated after adjustment. Longitudinal immune monitoring demonstrated persistent CD4 lymphopenia through 6 months, sustained inversion of the CD4:CD8 ratio, and declining IgG at months 3 and 6. In the cardiac sub-cohort (24 patients; 87 IL-2 doses), post-dose hs-Tn ≥15 ng/L was associated with clinically significant cardiac events (OR 9.6, 95% CI 1.5–60.6; p = 0.016) and IL-2 interruption (OR 3.4, 95% CI 1.1–10.7; p = 0.036). For cardiac events, hs-Tn ≥15 ng/L had 100% sensitivity and 100% negative predictive value. Conclusions: In routine practice, TIL therapy was feasible and active in metastatic melanoma. M1d disease identified a subgroup with poor survival, peri-dose hs-Tn showed promise as a tool to support safer IL-2 delivery, and prolonged CD4 suppression with IgG decline suggests that recovery after TIL therapy extends beyond initial hematologic reconstitution. These findings support prospective validation of biomarker-guided IL-2 monitoring and extended post-treatment immune surveillance.
Correlation between circulating tumor DNA and radiographic disease status in soft tissue sarcoma: A Mayo Clinic experience.
Orosco-Ttamina, Angel Luis , Seetharam, ­Mahesh

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e23554 Get It

e23554 Background: Radiographic imaging remains the standard of care for disease surveillance and response assessment in soft tissue sarcoma (STS). Circulating tumor DNA (ctDNA) has emerged as a potential biomarker in solid tumors; however, its feasibility and detectability in STS remain incompletely defined due to histologic heterogeneity and variable tumor DNA shedding. We evaluated ctDNA detectability and its relationship to radiographic disease status in the most common STS subtypes: undifferentiated pleomorphic sarcoma (UPS) and leiomyosarcoma (LMS). Methods: We retrospectively analyzed patients with UPS or LMS who underwent serial ctDNA testing using a personalized assay (Signatera) alongside routine radiographic surveillance between 2022 and 2025. Any detectable mean tumor molecules (MTM) >0 was considered positive. ctDNA results were paired with the closest imaging within ±30 days and assessed using radiology report–based determinations of disease status. Exploratory sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were estimated per paired assessment using radiographic progression or recurrence as the reference standard. Results: 13 patients were included (7 female, 6 male), with a median age of 62 years (range 28–75); 7 patients (54%) had LMS and 6 (46%) had UPS. A total of 59 ctDNA–imaging paired assessments were analyzed (median 4 per patient). Overall ctDNA detectability was low and histology-dependent. Baseline ctDNA was detectable in 2 of 13 patients (15%), both with LMS. During longitudinal follow-up, ctDNA remained persistently undetectable in 10 of 13 patients (77%), including all UPS patients and 4 of 7 LMS patients. Detectable ctDNA occurred almost exclusively in LMS and was often observed in association with radiographic disease progression. Across all paired assessments, 46 of 59 (78%) were concordant. Discordance included false-negative ctDNA (negative ctDNA with radiographic disease/progression; n=9) and transient ctDNA positivity without immediate radiographic progression (n=4). Where longitudinal follow-up was available, subsequent ctDNA or imaging assessments frequently demonstrated eventual alignment; lead-time analysis for transient positives was limited by sample size. Using radiographic progression as the reference standard, exploratory per-pair test characteristics demonstrated a sensitivity of approximately 64%, specificity of 88%, PPV of 80%, and NPV of 77%. Conclusions: In this real-world cohort, ctDNA detectability differed by histology and was observed predominantly in LMS. When detectable, ctDNA trends often aligned with radiographic disease progression or recurrence, supporting a potential complementary role in disease monitoring for selected patients. These findings require confirmation in larger, prospective studies.
Baseline visceral disease burden and treatment delivery factors association with outcomes after tumor-infiltrating lymphocyte therapy for metastatic melanoma.
Aboelatta, Mohamed A. , Zarka, Jabra, Tchatchua, Nika, Kavousi, Shahin , Behl, Deepti , Jakub, James W., Seetharam, ­Mahesh , Kottschade, Lisa A. , Block, Matthew Stephen, Montane, Heather N. , Markovic, Svetomir, Zarka, Jabra , Tchatchua, Nika , Zarka, Jabra G , Tchatchua, Nika , Johnson, Jeffrey A. , Jakub, James W. , Doonan, Bently P. , Dimou, A., Block, Matthew S. , Hieken, Tina J. , Dudek, Arkadiusz Z.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e21521 Get It

e21521 Background: Outcomes following tumor-infiltrating lymphocyte (TIL) therapy vary in real-world practice, and accessible predictors are needed to inform patient selection and timing of referral. We evaluated whether baseline disease burden, metastatic distribution, and treatment delivery factors are associated with outcomes following TIL therapy. Methods: We retrospectively analyzed patients with metastatic melanoma treated with TIL therapy across Mayo Clinic sites (N = 27 infused). Baseline disease burden was characterized using AJCC metastatic stage and organ-specific involvement. A composite high visceral burden variable was defined as the presence of M1d disease and/or liver metastases. Bridging therapy use prior to infusion was recorded. Post-infusion IL-2 exposure was categorized as low (0-2 doses) vs. high (3-6 doses). Best overall response (BOR) was summarized using RECIST-based standard criteria. Overall survival (OS) and progression-free survival (PFS) were measured from TIL infusion and estimated using Kaplan–Meier methods with univariable Cox regression. Results: Median age at infusion was 62.0 years; 59.3% were male. Melanoma subtypes included cutaneous (81.5%) and mucosal (18.5%). Bridging therapy was used in 48.1%. Baseline metastatic stage was M1a/M1b in 18.5%, M1c in 63.0%, and M1d in 18.5%. Median follow up was 8.3 months. BOR included complete response (18.5%), partial response (37.0%), stable disease (22.2%), and progressive disease (22.2%), yielding an objective response rate of 55.6% and disease control rate of 77.8%. Patients with high visceral disease burden experienced inferior OS vs. those without high visceral burden (median 5.2 vs 13.4 months; HR 4.77, 95% CI 1.22–18.63; p = 0.014). Bridging therapy was not associated with OS or PFS. Higher post-infusion IL-2 exposure (seen in 77.8% of patients) was associated with improved OS (median 9.0 vs 3.7 months; HR 0.16, 95% CI 0.04–0.67, p = 0.005), likely reflecting early post-infusion clinical tolerance rather than a causal treatment effect. Median PFS for the cohort was 3.6 months and did not differ by IL-2 exposure ( p = 0.3), metastatic stage ( p = 0.8), bridging therapy ( p = 0.7), liver metastases ( p = 0.2), or LDH above upper limit of normal ( p = 0.1). Conclusions: The above findings are hypothesis generating and will support evaluation in larger cohort. In this real-world cohort of patients treated with TIL therapy, baseline visceral disease burden was strongly associated with survival outcomes, while bridging therapy did not compromise post-infusion efficacy among patients proceeding to infusion. Post-infusion IL-2 exposure correlated with OS and likely reflects early treatment tolerance. These readily available clinical features may inform patient counseling, referral timing, and sequencing decisions as TIL therapy enters broader clinical use.
Pregnancy-associated progression with spontaneous postpartum regression in metastatic alveolar soft part sarcoma
Orosco-Ttamina, Angel Luis , Jones, Robin, Seetharam, ­Mahesh , Orosco-Ttamina, Angel Luis

Mayo Clinic

BMJ Case Reports | May 28, 2026 | Volume: 19 | Issue: 5 | Pages: e270772

10.1136/bcr-2025-270772 | PMID 42209029 Get It

We report the case of a woman with metastatic alveolar soft part sarcoma (ASPS) who experienced pregnancy-associated disease progression followed by unexpected postpartum regression. Pulmonary lesions increased in size after a miscarriage and during a subsequent pregnancy, prompting consideration for systemic treatment and potential enrolment in a clinical trial evaluating a tyrosine kinase inhibitor in combination with an immune checkpoint inhibitor. However, baseline staging CT performed a few weeks postpartum unexpectedly demonstrated marked spontaneous regression. Because trial enrolment required Response Evaluation Criteria in Solid Tumors-defined radiographic progression, she was deemed ineligible, and no systemic therapy was initiated. Surveillance imaging over the following 2 years confirmed sustained regression and stability of residual disease in the absence of treatment. This case highlights the potential influence of pregnancy-to-postpartum physiology on tumour behaviour through hormonal, immune and angiogenic mechanisms. It also emphasises the importance of short-interval reassessment after delivery before initiation of systemic therapy in reproductive-age patients with metastatic ASPS.
Real-world comparison of ipilimumab–nivolumab dosing strategies in melanoma brain metastases.
ELANTABLY, DINA, Parker, Jefferson , Hamilton, Jakob Skyler, White, Donnell, Abdel-Hakeem, Ahmed, Adeoye, Oluwatayo , Kamatham, Saivaishnavi , Maleski, Alina, Ashby, Frederick, Tan, Winston, Markovic, Svetomir, Block, Matthew S. , Seetharam, ­Mahesh , Dronca, Roxana , Chen, Ruqin, Elantably, Dina, Hamilton, Jakob Skyler, Ashby, Fay, Tan, Winston , Dudek, Arkadiusz Z. , McWilliams, Robert R. , Dimou, Anastasios

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 9558-9558

10.1200/jco.2026.44.16_suppl.9558 Get It

9558 Background: Ipilimumab 3 mg/kg plus nivolumab 1 mg/kg (Ipi3+Nivo1) is the standard immunotherapy regimen for metastatic melanoma with brain metastases (MBM) but is associated with significant immune-related toxicity, particularly neurologic toxicity. Ipilimumab 1 mg/kg plus nivolumab 3 mg/kg (Ipi1+Nivo3) has demonstrated improved tolerability in extracranial melanoma, though comparative data in MBM are limited. We compared efficacy and toxicity of these dosing strategies in a multisite real-world cohort. Methods: We retrospectively identified patients with MBM treated with ipilimumab plus nivolumab across three Mayo Clinic sites between 2016 and 2024. Patients were classified by induction dosing as Ipi1+Nivo3 or Ipi3+Nivo1. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method and compared using log-rank tests. Best overall response (BOR) and toxicity outcomes were summarized descriptively. Results: Among 147 patients (Ipi1+Nivo3 n=32; Ipi3+Nivo1 n=115), 144 were evaluable for survival. Median age was higher in the Ipi1+Nivo3 group (69.5 vs 66.0 years); males predominated in both groups (71.9% vs 61.7%), and the cohort was predominantly White (>96%). Most patients had ECOG 0–1 in both groups (84.4% in Ipi1+ Nivo3 and 90.4% in Ipi3+Nivo1). BRAF mutation status was balanced between regimens, with approximately half of patients harboring BRAF-mutant disease (51.6% vs 53.2%). Median OS was 18.5 months (95% CI, 5.7–54.7) with Ipi1+Nivo3 versus 10.6 months (95% CI, 6.5–19.1) with Ipi3+Nivo1 (log-rank p=0.25). Two-year OS was 45.9% and 35.0%, and five-year OS was 24.5% and 19.2%, respectively. Median PFS was 7.3 months (95% CI, 1.8–10.9) versus 2.8 months (95% CI, 2.1–4.4) (log-rank p=0.16). BOR was available for 138 patients; objective response rates were 35.5% and 31.8%, respectively. 3–5 adverse events occurred in 24.1% of Ipi1+Nivo3 versus 30.5% of Ipi3+Nivo1 patients. Hospitalizations were less frequent (16.7% vs 36.1%), and neurologic adverse events occurred only with Ipi3+Nivo1 (11.9% vs 0%). Conclusions: In this multisite real-world MBM cohort, Ipi1+Nivo3 demonstrated comparable efficacy, numerically longer survival, and a more favorable toxicity profile compared with standard Ipi3+Nivo1. Notably, no neurologic toxicity was observed with the Ipi1+Nivo3 regimen. These findings support further prospective evaluation of lower dose ipilimumab strategies. Response and survival outcomes. Outcome Ipi1 + Nivo3 Ipi3 + Nivo1 Complete response (CR) 2 / 31 (6.5%) 8 / 107 (7.5%) Partial response (PR) 9 / 31 (29.0%) 26 / 107 (24.3%) Objective response rate (ORR = CR+PR) 11 / 31 (35.5%) 34 / 107 (31.8%) Disease control rate (DCR = CR+PR+SD) 18 / 31 (58.1%) 51 / 107 (47.7%) Median PFS, months (95% CI) 7.3 (1.8–10.9) 2.8 (2.1–4.4) 2-year PFS 27.6% 22.3% Median OS, months (95% CI) 18.5 (5.7–54.7) 10.6 (6.5–19.1) 2-year OS 45.9% 35.0% 5-year OS 24.5% 19.2%